Free shipping on all orders over $ 500

AP26113

Cat. No. M1720

AP26113 Structure

Synonym: Brigatinib

Size Price Availability Quantity
5mg USD 100 In stock
10mg USD 180 In stock
50mg USD 450 In stock
Bulk Inquiry?

Quality Control
Biological Activity

AP26113 is a highly potent ALK inhibitor with IC50 of 0.62 nM. As an ALK inhibitor, AP26113 overcomes mutation-based resistance in NSCLC models. Multiple mutations in ALK were identified that conferred resistance to crizotinib, but not AP26113, including the L1196M "gatekeeper" mutation which has now been observed clinically in patients who initially responded to crizotinib and then relapsed. AP26113 also inhibits activated EGFR in preclinical models, including the T790M "gatekeeper" mutant that confers resistance to current EGFR inhibitors. Constitutive EGFR activity due to activating mutation is a key feature of certain non-small cell lung cancers, and the T790M mutation causes resistance to inhibitor therapy in approximately 50 percent of these cases. In preclinical studies, AP26113 was shown to be specific for mutated EGFR and avoids inhibition of native (endogenous or unmutated) EGFR; such inhibition is thought to be associated with the toxicity of other EGFR inhibitors.

Protocol
Cell Experiment
Cell lines H3122, H3122 CR, A549, H1299, SKBR3, H522, H460, and BT474 cells
Preparation method Survival assays
For 72-h drug treatments, 3000 cells were plated in replicates of six into 96-well plates. Following drug treatments, cells were incubated with CellTiter-Glo assay reagent (Promega) for 10 min and luminescence was measured using a Centro LB 960 microplate luminometer (Berthold Technologies).
Concentrations 0~1µ M
Incubation time 72 h
Animal Experiment
Animal models H3122 CR xenografts in athymic nude mice
Formulation saline
Dosages 50 mg/kg/day for 17 days
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 529.01
Formula C26H34ClN6O2P
CAS Number 1197958-53-4
Purity >99%
Solubility DMSO
Storage at -20°C
References

Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC.
Victor et al. Cancer Research. 2012 April 15;Volume 72, Issue 8, Supplement 1.

Related ALK Products
Entrectinib (RXDX-101)

Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.

Crizotinib hydrochloride

Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK. Crizotinib inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Crizotinib is useful in treatment of anaplastic large-cell lymphoma.

Brigatinib

Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.

ALK-IN-1

ALK-IN-1 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.

CEP-37440

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: AP26113, Brigatinib supplier, ALK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.